Vogenx, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Vogenx, Inc. (VOGX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.67 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-17.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-09-17
- Vogenx, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.67K, a 78.10% increase year-over-year.
- Vogenx, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was -$4.85K, a 285.12% decline year-over-year.
- Vogenx, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.62K.
- Vogenx, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $2.62K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month |
|---|---|---|
| 2026-06-30 | $4.67K 10-Q · filed 2026-09-17 | -$184.00 derived: sum of 2 quarters · filed 2026-09-17 |
| 2026-03-31 | -$4.85K 10-Q · filed 2026-09-17 | |
| 2025-06-30 | $2.62K 10-Q · filed 2026-09-17 | $5.24K derived: sum of 2 quarters · filed 2026-09-17 |
| 2025-03-31 | $2.62K 10-Q · filed 2026-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |